pyrroles has been researched along with hki 272 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashrafi, GH; Modjtahedi, H; Seddon, AM; Stanley, A | 1 |
| Abraham, J; Baird, RD; Bliss, JM; Braybrooke, JP; Bye, H; Cameron, D; Cutts, R; Gevensleben, H; Hubank, M; Kernaghan, S; Kilburn, LS; Kingston, B; Macpherson, IR; Martin, S; Moretti, L; Oikonomidou, O; Randle, K; Rea, D; Ring, A; Roylance, R; Shaaban, A; Snowdon, C; Stephens, P; Turner, NC; Tuthill, M; Wardley, AM; Wilkinson, K; Winter, MC | 1 |
1 trial(s) available for pyrroles and hki 272
| Article | Year |
|---|---|
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Estrogen Receptor alpha; Female; Fulvestrant; Genotype; Humans; Middle Aged; Molecular Targeted Therapy; Mutation; Prospective Studies; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2020 |
1 other study(ies) available for pyrroles and hki 272
| Article | Year |
|---|---|
Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines.
Topics: Afatinib; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Enlargement; Cell Line, Tumor; Cell Movement; Crizotinib; Dasatinib; Female; Humans; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Pyrroles; Quinolines; Receptor, ErbB-2; Receptor, IGF Type 1; src-Family Kinases | 2017 |